Berberine combined with atorvastatin downregulates LOX-1 expression through the ET-1 receptor in monocyte/macrophages

International Journal of Molecular Medicine

Volumn 34, Issue 1, 2014, Pages 283-290

  Chi, Liyi ^a   Peng, Lijing ^a   Hu, Xiaojing ^b   Pan, Na ^a   Zhang, Yanhai ^a  

^a Interventional Therapeutic Center   (China)

^b The Ninth Hospital of Xi'an City   (China)

Author keywords

Atorvastatin; Berberine; Endothelin 1 receptor; Lectin like oxidized low density lipoprotein receptor 1; Monocyte derived macrophages

Indexed keywords

ATORVASTATIN; BERBERINE; ENDOTHELIN 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; TRIACYLGLYCEROL; CHOLESTEROL; ENDOTHELIN A RECEPTOR; FAT INTAKE; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; OLDLR1 PROTEIN, RAT; PYRROLE DERIVATIVE; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOWN REGULATION; HEART WEIGHT; KIDNEY MASS; MACROPHAGE; MALE; MOLECULAR MECHANICS; MONOCYTE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPLEEN WEIGHT; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CELL CULTURE; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; FAT INTAKE; GENE EXPRESSION REGULATION; GENETICS; LIPID DIET; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; BERBERINE; BODY WEIGHT; CELLS, CULTURED; CHOLESTEROL; DIET, HIGH-FAT; DIETARY FATS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GENE EXPRESSION REGULATION; HEPTANOIC ACIDS; MACROPHAGES; MALE; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; RNA, SMALL INTERFERING; SCAVENGER RECEPTORS, CLASS E; SIGNAL TRANSDUCTION; TRIGLYCERIDES;

EID: 84902688573     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2014.1748     Document Type: Article

References (42)

1. Lusis AJ: Atherosclerosis. Nature 407: 233-241, 2000.
2. Li J, Chen CX and Shen YH: Effects of total glucosides from paeony (Paeonia lactiflora Pall) roots on experimental atherosclerosis in rats. J Ethnopharmacol 135: 469-475, 2011.
3. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352: 1685-1695, 2005.
4. Pentikäinen MO, Oörni K, Ala-Korpela M and Kovanen PT: Modified LDL-trigger of atherosclerosis and inflammation in the arterial intima. J Intern Med 247: 359-370, 2000. (Pubitemid 30180038)
5. Plihtari R, Kovanen PT and Öörni K: Acidity increases the uptake of native LDL by human monocyte-derived macrophages. Atherosclerosis 217: 401-406, 2011.
6. Libby P, Ridker PM and Maseri A: Inflammation and athero-sclerosis. Circulation 105: 1135-1143, 2002.
7. Stein S, Lohmann C, Schäfer N, et al : SIRT1 decreases Lox-1-mediated foam cell formation in atherogenesis. Eur Heart J 31: 2301-2309, 2010.
8. Levitan I, Volkov S and Subbaiah PV: Oxidized LDL: diversity, patterns of recognition, and pathophysiology. Antioxid Redox Signal 13: 39-75, 2010.
9. Kakutani M, Masaki T and Sawamura T: A platelet-endothelium interaction mediated by lectin-like oxidized low-density lipo-protein receptor-1. Proc Natl Acad Sci USA 97: 360-364, 2000. (Pubitemid 30055836)
10. Chen M, Kakutani M, Naruko T, et al: Activation-dependent surface expression of LOX-1 in human platelets. Biochem Biophys Res Commun 282: 153-158, 2001. (Pubitemid 32924358)
11. Kataoka H, Kume N, Miyamoto S, et al: Oxidized LDL modulates Bax/Bcl-2 through the lectinlike Ox-LDL receptor-1 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 21: 955-960, 2001. (Pubitemid 34168652)
12. Mitra S, Goyal T and Mehta JL: Oxidized LDL, LOX-1 and atherosclerosis. Cardiovasc Drugs Ther 25: 419-429, 2011.
13. Yamamoto N, Toyoda M, Abe M, et al: Lectin-like oxidized LDL receptor-1 (LOX-1) expression in the tubulointerstitial area likely plays an important role in human diabetic nephropathy. Intern Med 48: 189-194, 2009.
14. Nagase M, Hirose S, Sawamura T, Masaki T and Fujita T: Enhanced expression of endothelial oxidized low-density lipo-protein receptor (LOX-1) in hypertensive rats. Biochem Biophys Res Commun 237: 496-498, 1997. (Pubitemid 27434712)
15. Rautureau Y and Schiffrin EL: Endothelin in hypertension: an update. Curr Opin Nephrol Hypertens 21: 128-136, 2012.
16. Taguchi K and Hattori Y: Unlooked-for significance of cardiac versus vascular effects of endothelin-1 in the pathophysiology of pulmonary arterial hypertension. Circ Res 112: 227-229, 2013.
17. Watson AM, Li J, Schumacher C, et al : The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice. Diabetologia 53: 192-203, 2010.
18. Rodríguez-Pascual F, Busnadiego O, Lagares D and Lamas S: Role of endothelin in the cardiovascular system. Pharmacol Res 63: 463-472, 2011.
19. Morawietz H, Rueckschloss U, Niemann B, et al: Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Circulation 100: 899-902, 1999.
20. Böhm F and Pernow J: The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc Res 76: 8-18, 2007. (Pubitemid 47362047)
21. Xu S, Liu Z, Huang Y, et al: Tanshinone II-A inhibits oxidized LDL-induced LOX-1 expression in macrophages by reducing intracellular superoxide radical generation and NF-κB activation. Transl Res 160: 114-124, 2012.
22. Kang B-Y, Khan JA, Ryu S, Shekhar R, Seung KB and Mehta JL: Curcumin reduces angiotensin II-mediated cardiomyocyte growth via LOX-1 inhibition. J Cardiovasc Pharmacol 55: 176-183, 2010.
23. Guan S, Wang B, Li W, Guan J and Fang X: Effects of berberine on expression of LOX-1 and SR-BI in human macrophage-derived foam cells induced by ox-LDL. Am J Chin Med 38: 1161-1169, 2010.
24. Ou H-C, Song T-Y, Yeh Y-C, et al: EGCG protects against oxidized LDL-induced endothelial dysfunction by inhibiting LOX-1-mediated signaling. J Appl Physiol (1985) 108: 1745-1756, 2010.
25. Chang H-C, Chen T-G, Tai Y-T, Chen T-L, Chiu W-T and Chen R-M: Resveratrol attenuates oxidized LDL-evoked Lox-1 signaling and consequently protects against apoptotic insults to cerebrovascular endothelial cells. J Cereb Blood Flow Metab 31: 842-854, 2011.
26. Kuo C-L, Chi C-W and Liu T-Y: The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett 203: 127-137, 2004. (Pubitemid 38063132)
27. Brusq J-M, Ancellin N, Grondin P, et al: Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res 47: 1281-1288, 2006. (Pubitemid 43830720)
28. Puato M, Faggin E, Rattazzi M, et al: Atorvastatin reduces macrophage accumulation in atherosclerotic plaques: a comparison of a nonstatin-based regimen in patients undergoing carotid endarterectomy. Stroke 41: 1163-1168, 2010.
29. Zhou G, Ge S, Liu D, et al : Atorvastatin reduces plaque vulnerability in an atherosclerotic rabbit model by altering the 5-lipoxygenase pathway. Cardiology 115: 221-228, 2010.
30. Simmons G, McKnight À, Takeuchi Y, Hoshino H and Clapham PR: Cell-to-cell fusion, but not virus entry in macrophages by T-cell line tropic HIV-1 strains: a V3 loop-determined restriction. Virology: 209: 696-700, 1995.
31. McKnight Á, Griffiths DJ, Dittmar M, Clapham P and Thomas E: Characterization of a late entry event in the replication cycle of human immunodeficiency virus type 2. J Virol 75: 6914-6922, 2001. (Pubitemid 32641578)
32. Sitia S, Tomasoni L, Atzeni F, et al: From endothelial dysfunction to atherosclerosis. Autoimmun Rev 9: 830-834, 2010.
33. Pawlak K, Mysliwiec M and Pawlak D: Oxidized LDL to auto-antibodies against oxLDL ratio-the new biomarker associated with carotid atherosclerosis and cardiovascular complications in dialyzed patients. Atherosclerosis 224: 252-257, 2012.
34. Howell KW, Meng X, Fullerton DA, Jin C, Reece TB and Cleveland JC Jr: Toll-like receptor 4 mediates oxidized LDL-induced macrophage differentiation to foam cells. J Surg Res 171: e27-e31, 2011.
35. Lu J, Mitra S, Wang X, Khaidakov M and Mehta JL: Oxidative stress and lectin-like ox-LDL-receptor LOX-1 in atherogenesis and tumorigenesis. Antioxid Redox Signal 15: 2301-2333, 2011.
36. Pandey H, Arjuman A, Roy KK and Chandra NC: Reciprocal coordination of a combination oral contraceptive containing desogestrel+ethinyl estradiol on the expression of LOX-1 and LDLR in placental trophoblast cells. Contraception 84: e43-e49, 2011.
37. NAVIGATOR Study Group, McMurray JJ, Holman RR, Haffner SM, et al: Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 362: 1477-1490, 2010.
38. Morawietz H, Duerrschmidt N, Niemann B, Galle J, Sawamura T and Holtz J: Induction of the oxLDL receptor LOX-1 by endothelin-1 in human endothelial cells. Biochem Biophys Res Commun 284: 961-965, 2001. (Pubitemid 32924741)
39. Cani PD, Bibiloni R, Knauf C, et al: Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57: 1470-1481, 2008.
40. Zhang X, Dong F, Ren J, Driscoll MJ and Culver B: High dietary fat induces NADPH oxidase-associated oxidative stress and inflammation in rat cerebral cortex. Exp Neurol 191: 318-325, 2005. (Pubitemid 40092875)
41. Ju J, Liu Y, Hong J, Huang MT, Conney AH and Yang CS: Effects of green tea and high-fat diet on arachidonic acid metabolism and aberrant crypt foci formation in an azoxymethane-induced colon carcinogenesis mouse model. Nutr Cancer 46: 172-178, 2003. (Pubitemid 37500509)
42. Lee JY, Sohn KH, Rhee SH and Hwang D: Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem 276: 16683-16689, 2001.